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Abstract The longstanding notion that head and neck
squamous cell carcinoma (HNSCC) is a uniform disease
process is changing. Divergence in epidemiologic trends
among HNSCCs arising in different anatomic subsites has
introduced a view that HNSCC is a heterogeneous group.
Analysis of molecular genetic changes discloses not just
individual tumor differences, but also consistent large-scale
differences that permit the recognition of important tumor
subtypes. One recently recognized subtype is the human
papillomavirus (HPV)-positive oropharyngeal carcinoma.
HPV-positive oropharyngeal cancer now dominates the
head and neck oncology landscape, and its escalating
incidence is impacting on diagnostic, preventive and ther-
apeutic practices.
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Introduction
Long regarded as a uniform group of tumors that differed
only as a function of anatomic site, ongoing studies indi-
cate that HNSCCs may not be as homogenous as
previously supposed. Recognition of distinct molecular
genetic proﬁles now permits ﬁner resolution of HNSCC
into distinct subtypes that differ with respect to risk factors,
pathogenesis, and clinical behavior [1]. HPV-associated
oropharyngeal carcinoma has recently been recognized as a
unique subtype of HNSCC [2]. HPV status has a profound
effect on patient prognosis, and it may soon guide therapy.
Accordingly, HPV status will become a standard compo-
nent in the diagnostic reporting of all oropharyngeal
carcinomas. This review covers recent advances toward
deﬁning HPV-related oropharyngeal carcinoma, and draws
speciﬁc attention to pathology concerns that impact on the
diagnosis and reporting of these cancers.
Discussion
HNSCC is the eighth most common cancer worldwide with
approximately 650,000 new cases reported annually.
Beginning in the early 1980s, the incidence of HNSCC in
the United States and elsewhere has been in retreat. This
downward trend has roughly paralleled trends in smoking.
Accordingly, HNSCC is often perceived as a preventable
disease, and its ultimate demise simply a matter of
implementing behavior modiﬁcation strategies. This great
optimism has recently been shaken by a sobering escalation
of a speciﬁc type of cancer that is asserting its dominance
on the head and neck oncology landscape. Speciﬁcally, the
incidence of oropharyngeal cancer is advancing [3, 4]. This
anomalous rise bucks the prevailing notion that HNSCC
incident rates can be controlled through smoking preven-
tion and cessation. Indeed, the escalation of oropharyngeal
carcinoma points to the participation of non-traditional
behavioral and environmental factors driving this disturb-
ing epidemiologic trend.
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DOI 10.1007/s12105-009-0100-yThe prototypic patient with oral cancer is an older man
whohassmokedcigarettesanddrankalcoholformanyyears.
This prototype, however, no longer ﬁts the patient with oral
cancer whonowentersthedoorsofourclinicsandhospitals.
Patients now tend to be younger (between 40 and 60 years)
white men who have never smoked cigarettes or drank
alcohol [5]. Traditional risk factors have been supplanted by
other powerful risk factors relating to sexual practices, the
most important of these being high number of sexual part-
ners, history of oral-genital sex, and history of oral-anal sex
[5, 6]. Oral anogenital contact is an important route for the
transmission of HPV to the oral cavity. Certain conditions
and behaviors that alter antitumor immunity may be
important in transforming an HPV oral infection towards
HPV-related malignancy. As one example, marijuana use
has recently been identiﬁed as an independent risk factor for
HPV-positive HNSCC, and the strength of this association
increases with intensity, duration, and cumulative years of
marijuana smoking [7]. Long scrutinized as a potential
source of DNA-damaging carcinogens, marijuana smoke
may be more relevant for its immunomodulatory effects.
Cannabinoids bind to the CB2 receptor expressed on
immunomodulatory cells in human tonsillar tissue. Binding,
in turn, can suppress immune responses, diminish host
responsestoviralpathogens,andattenuateantitumoractivity.
HPV, particulary type 16, is detected in about 70% of
oropharyngeal carcinomas. These HPV-positive cancers
are increasingly recognized as a distinct subgroup of
HNSCC with a biological and clinical proﬁle that diverges
from that of their HPV-negative counterparts (Table 1). At
the molecular genetic level, HPV-positive HNSCCs
express the viral oncoproteins E6 and E7, overexpress the
p16 gene product, and only infrequently harbor p53 gene
mutations. Regarding clinical behavior, HPV16-positive
HNSCs are associated with an improved prognosis [8, 9].
The mechanisms underlying this favorable prognosis may
involve the combined effects of immune surveillance to
viral-speciﬁc tumor antigens, an intact apoptotic response
to radiation, and the absence of widespread genetic alter-
ations associated with smoking (i.e., ﬁeld cancerization).
The pathologic features of HPV-positive HNSCs also
deviate from the moderately differentiated keratinizing
morphology that typiﬁes most HNSCCs. HPV-positive
HNSCCs consistently: (1) arise from the tonsillar crypts;
(2) are unassociated with dysplasia of the surface epithe-
lium; (3) exhibit lobular growth; (4) are permeated by
inﬁltrating lymphocytes; (5) lack signiﬁcant keratinization;
and (6) demonstrate a prominent ‘‘basaloid’’ morphology
(Fig. 1). Two microscopic features of HPV-related oro-
pharyngeal cancers are likely to cause diagnostic ambiguity.
First, HPV-related HNSCC is customarily misperceived as
a poorly differentiated carcinoma based on the immature
appearance of the tumor cells. In point of fact, the appear-
ance of the tumor cells closely emulates the appearance of
the reticulated epithelium—the specialized epithelium lin-
ing the tonsillar crypts from which HPV-related cancers
arise [10]. In other words, HPV-related oropharyngeal
cancers are in fact highly differentiated, not poorly
Table 1 Comparison of HPV-positive and HPV-negative head and
neck cancers
HPV-positive HPV-negative
Incidence Increasing Decreasing
Age Younger Older
Gender 3:1 men 3:1 men
Risk factors Sexual behavior Tobacco,
alcohol
Cofactors Marijuana,
immunosuppression
Diet, oral hygiene
Molecular genetics
ﬁndings
P16 : P16 ;
Rb ; Rb :
P53 wild-type P53 mutated
Anatomic site Lingual and palatine tonsils All sites
Pathologic ﬁndings
Primary Basaloid Keratinized
Lymph node
metastasis
Cystic Solid
Survival Better Worse
Fig. 1 Typical histopathologic
appearance of an HPV-related
cancer of the head and neck.
a The carcinomas tend to arise
from the tonsillar crypts and
inﬁltrate the lymphoid stroma as
expanding tumor lobules. b The
lobules of tumor cells are
permeated by lymphocytes, lack
keratinization, and have a
basaloid appearance
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‘‘basaloid’’ as a diagnostic descriptor is confusing for the
way it invites an erroneous connection with basaloid
squamous cell carcinoma—a subtype of HNSCC notorious
for its aggressive clinical behavior. Within the basaloid
subtype, detection of HPV is a highly favorable prognostic
factor that helps identify a subset of cancers that departs
from the highly aggressive behavior associated with this
variant [11]. Until consensus panels put forward a classiﬁ-
cation scheme for oropharyngeal carcinomas that
underscores their relationship with HPV while avoiding
confusion with the aggressive basaloid variant, it is our
practice to: (1) classify these tumors as non-keratinizing
squamous cell carcinomas, (2) suspend the use of the
descriptors such as ‘‘poorly differentiated’’ and ‘‘basaloid’’,
and (3) routinely report on the HPV status of all HNSCCs
arising in the oropharynx.
Determination of HPV status will certainly become
standard practice in the pathologic evaluation of oropha-
ryngeal cancers. As a biomarker, HPV detection is
emerging as a valid method of discerning the presence and
progress of disease encompassing all aspects of patient care
from early cancer detection, to tumor localization [12]
(Fig. 2), to selection of patients most likely to beneﬁt from
speciﬁc therapies, to post-treatment tumor surveillance. A
variety of detection methods are in current use including
PCR-based strategies, type-speciﬁc in situ hybridization
(ISH) techniques, and immunohistochemical detection of
surrogate biomarkers (e.g. p16 protein). Standardization of
HPV detection in the clinical arena must begin with selec-
tion of the best detection platform for universal application.
The preferential use of ISH methods over PCR-based
methods is supported both by biological and practical
considerations. The reported large variation of HPV prev-
alence in HNSCC is a largely a reﬂection of the inability of
non-quantitative PCR methods to discern virus that is
biologically meaningful from virus that is biologically
irrelevant. In contrast, punctuate hybridization signals
within the nuclei of tumor cells is a pattern of staining only
seen following HPV DNA integration into the host
genome, and thus is more closely linked with relevant viral
infections. Importantly, the improved speciﬁcity of HPV
detection by ISH does not come at the expense of sensi-
tivity. The introduction of various signal ampliﬁcation
steps has signiﬁcantly improved the sensitivity of this
technique, even to the point of viral detection down to one
viral copy per cell. The development of nonﬂuorescent
chromogens now allows visualization of DNA hybridiza-
tion using conventional light microscope. Adaptation of
ISH to formalin-ﬁxed and parafﬁn-embedded tissues has
made this technique compatible with standard tissue-pro-
cessing procedures and amendable to retrospective analysis
of archival tissue blocks while most PCR-based methods
are optimized to fresh frozen samples. ISH is a feasible and
cost-effective test for most diagnostic laboratories that
routinely process formalin-ﬁxed and parafﬁn-embedded
tissue blocks.
In HPV-positive oropharyngeal carcinomas, functional
inactivation of Rb by the viral oncoprotein E7 is known to
induce an up regulation of p16 expression, reaching levels
that can be readily detected by routine immunohisto-
chemistry. Accordingly, p16 immunohistochemistry is
often advocated as a reliable surrogate marker of HPV-
induced neoplasia of oropharynx. Direct comparison of p16
immunohistochemical staining and HPV-16 ISH for large
numbers of HNSCCs reveals a discrepancy rate of about
25%. In a subset of discrepant cases, high p16 expression is
due to the presence of some other (non-16) HPV type as
conﬁrmed by wide spectrum ISH. The remaining discrep-
ancies likely reﬂect the imperfection of p16 as a surrogate
marker. Using E6/E7 mRNA levels as conclusive evidence
of HPV involvement, positive p16 immunostaining of
HNSCCs is 100% sensitive but only 79% speciﬁc [13].
The limitations of any single detection assay may be
offset using algorithms that combine the strengths of
complementary assays. We use a detection strategy that
combines HPV ISH with p16 immunohistochemistry.
Given a sensitivity that approaches 100%, p16 immuno-
staining is a good ﬁrst line assay for eliminating HPV-
negative cases from additional analysis. HPV-16 ISH can
Fig. 2 Metastatic squamous
cell carcinoma of unknown
primary origin. The metastasis
is cystic (a, hematoxylin and
eosin). The presence of HPV as
evident by p16
immunohistochemical staining
(b) and HPV-16 in situ
hybridization (hybridization
dots within tumor cell nuclei,
inset) point to the oropharynx as
the site of tumor origin
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second-line assay following a positive p16 result. Given a
speciﬁcity approaching 100%, a positive HPV-16 ISH
reduces the numbers of false positive cases by p16 staining
alone. A p16-positive/HPV-16-negative result singles out a
subset of tumors that qualify for rigorous analysis for other
(i.e. non-16) oncogenic HPV types. For this third-line
assay, we use a consensus ISH probe that that detects an
extended panel of HPV types. P16 immunohistochemistry
and HPV ISH are standardized techniques that are easily
applied to formalin-ﬁxed and parafﬁn-embedded tissues.
As automated ISH technologies are brought on-line, turn-
around time will be further shortened and standardization
across various diagnostic laboratories will be enhanced.
Conclusion
Incident trends for HNSCC have generally paralleled
smoking trends. The escalating incidence of oropharyngeal
carcinoma in the absence of a parallel rise in smoking and
alcohol consumption suggests that nontraditional behav-
ioral and environmental factors are driving this aberration.
HPV, particularly type 16, has been established as a
causative agent in up to 70% of oropharyngeal cancers.
These HPV-positive HNSCCs differ in important respects
from HPV-negative HNSCC including risk factors,
molecular genetic alterations, microscopic appearance, and
clinical behavior. Diagnostic pathologists are now faced
with the challenge of accurately discerning HPV status of
oropharyngeal cancers.
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